Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from EXACT Therapeutics AS ( (DE:56F) ) is now available.
EXACT Therapeutics announced promising pre-clinical results for its Acoustic Cluster Therapy (ACT®) in immune oncology, which will be presented at the Ninth International Cancer Immunotherapy Conference. The data, developed in collaboration with NTNU and ICR, show increased uptake of checkpoint inhibitors in prostate cancer and potential immunostimulatory effects in melanoma and breast cancer models, potentially enhancing the company’s position in precision oncology.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company specializing in targeted drug delivery using ultrasound and microbubbles, primarily in oncology. The company’s proprietary Acoustic Cluster Therapy (ACT®) is designed to enhance the efficacy of therapeutic agents across various medical conditions, including cancer and brain diseases. EXACT Therapeutics is publicly traded on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 29,869
Current Market Cap: NOK156.9M
See more data about 56F stock on TipRanks’ Stock Analysis page.